Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rotational vs Sequential Abiraterone and Apalutamide in mCRPC
NCT03173859Phase 2Withdrawn
- Sponsor
- National and Kapodistrian University of Athens
- Start
- Jan 2018
- Primary completion
- Dec 2020
- Modality
- Orthosteric Ligands
01
Overview
Phase 2, randomised, open-label trial of Abiraterone Acetate Tablets (I) and apalutamide in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by National and Kapodistrian University of Athens. Primary endpoint: Radiographic Progression-Free Survival at 24 months. Planned start Jan 2018; status: withdrawn.
02
Drugs
Abiraterone Acetate Tablets (I)apalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03173859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03173859.